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The primary research aims were to understand the relationship between maternal 
postpartum body iron and birth and 4-month infant body iron and to determine if maternal 
or newborn iron status was a predictor of first year illness. Subjects were 199 pregnant 
women and their infants. Subjects were a convenience sample from a phase III randomized 
controlled trial that studied docosahexanoic acid during pregnancy. Medical records and 
adverse events from parent reports provided incidence of first year illnesses. Blood was 
obtained for the primary study and analyzed for iron values used in the secondary analysis. 
Maternal iron status was determined by 28-week hemoglobin, postpartum plasma ferritin, 
and postpartum plasma transferrin receptor; and infant iron status was determined by 
plasma transferrin receptor and plasma ferritin from cord blood and 4-month blood.  
Maternal postpartum body iron was not correlated with neonatal body iron from cord 
blood or infant blood at 4-months. Maternal postpartum plasma ferritin was inversely 
correlated with infant body iron at 4-months (r=-.229, p=.029). Newborn body iron 
correlated with 4-month body iron (r=.240, p=.047). We found a small but significant 
inverse relationship between maternal iron status at delivery and infant iron status at 4-
months. We did not find a significant relationship between maternal or infant iron status 
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Iron is a primary component of the body’s immune system (1). The risk of infection 
increases when iron deficiency anemia is present (2, 3). Pregnant women and children are 
at the highest risk for iron deficiency anemia and consequently impaired immunity (4). 
Iron losses from menses can result in low iron stores in women of reproductive age and the 
iron needs of the growing fetus during pregnancy can increase these deficits (5). The sole 
source of neonatal iron during pregnancy is maternal iron (6). The placenta carries 
nutrients to the fetus (7). The role maternal iron plays in the development of neonatal iron 
stores remains inconclusive in existing literature.  
Both high and low maternal iron states have been associated with adverse outcomes 
for the newborn. Serum ferritin >41ng/mL during the 3rd trimester was associated with a 
preterm or very preterm delivery (8). Zhou et al. (9) found that hemoglobin >130g/L in the 
first trimester posed a risk of low infant birth weight and preterm delivery. However, 
Scalon et al. (10) did not find a relationship between preterm delivery and high hemoglobin 
in the 1st or 2nd trimester.  
In an observational study, to investigate the association between maternal iron 
deficiency anemia and infant iron status at 9 months of age, Savoie and Rioux (11) found a 
positive correlation between the mother’s hemoglobin (p=0.02) and hematocrit (p=0.04) 
during the 3rd trimester and the infant’s hemoglobin and hematocrit at 9 months of age. 
They also found that infants born to women with iron deficiency anemia were more likely 
to be diagnosed with iron-deficiency anemia (p=0.055). Zhou, Gibson, and Makrides (12) 
studied the relationship of maternal and neonatal iron status with maternal iron 
supplementation during pregnancy. They found no effect of maternal iron supplementation 
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on hemoglobin or serum ferritin concentrations in infants, however, maternal hemoglobin 
at delivery and child hemoglobin at 4 years of age were related (p≤.03) (12). The positive 
relationship between maternal and neonatal hemoglobin in Zhou, Gibson, and Makrides 
(12) concurs with results of Savoie and Rioux’s (11) observational study.  
Studies of the relationship between iron and infant illness could further determine 
the importance of maternal or newborn iron status. Again, the literature is not consistent 
on whether iron supplementation in infancy reduces the number of infections in the first 
year of life. Only two studies have provided iron to newborn infants. Both occurred in 
populations of infants at risk for illness due to poverty, and only one found 
supplementation reduced hospitalization for illness. Cantwell studied illness rates in Maori 
infants, New Zealand natives, treated with injections totaling 250 mg of iron dextran 
(n=144) or no injection (n=94) in the infants first week of life. In the first two years of life 
42.4 of 100 children in the control group were hospitalized for infections compared to 31.9 
hospitalizations in the treatment group (13). Damodaran et al. (14) supplemented infants 
(n=383) from two Indian villages with 100 ug folate and 20 mg elemental iron per day for 
the first year of life or a placebo. They did not find a significant difference in the frequency 
or duration of respiratory or enteric infections after 6 or 12 months of supplementation. 
Statement of Purpose  
 The purpose of this secondary analysis is a) to compare maternal postpartum iron 
stores, plasma transferrin receptor and plasma ferritin, with infant iron status at birth and 
4-months of age and b) to compare maternal and newborn iron status at birth to the 
incidence of infant illness in the first year of life.  
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Primary Research Questions  
1) Are maternal postpartum body iron and infant body iron at birth and 4-months of 
age related?  








































Literature Review  
Introduction  
Iron is a primary constituent for the body’s immune system, cell growth, and cell 
differentiation (1). Neutrophils, a type of white blood cell, determine the ability of 
phagocytes to kill bacteria (15). Iron deficiency anemia impairs neutrophil activity (16). 
Neutrophils exhibit an oxidative burst after ingestion of bacteria that is dependent upon an 
iron-containing b cytochrome (15). Iron is a fundamental element of the enzyme 
myeloperoxidase, which is responsible for producing oxygen intermediates to kill 
pathogens (16). Cell-mediated immunity relies on thymus-derived lymphocytes (T-cells) 
(15) and studies (17, 18) reveal a reduced number of T-cells in iron-deficient pregnant 
women and children. Ribonucelotide reductase, an iron-containing enzyme, could be 
potentially responsible for the reduced number of T-cells in the presence of iron deficiency 
(15). Antigen-mediated immunity is normal in iron-deficient individuals (19, 20). 
In this paper, my purpose is to review the role of iron as a predictor of illness rates 
in infants. There is controversy surrounding iron supplementation during pregnancy. Some 
clinical studies have investigated the relationship between maternal and neonatal iron 
status after maternal iron supplementation during pregnancy or by comparing through 
maternal iron status before or after birth to the incidence of neonatal anemia. Potential 
factors that can influence iron status such as infant feeding, maternal body mass index, 
gestational days smoked, gestational age, and maternal ethnicity will be discussed.  
Iron is the most common micronutrient deficiency in the world (4). Anemia affects 
approximately 30% of the population, with the majority of cases being characterized as 
iron deficiency anemia. Approximately 18% of women in industrialized countries have iron 
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deficiency anemia (4, 21). Children and pregnant women are at the highest risk for iron 
deficiency anemia (4). Iron losses from menses can result in low iron stores in women of 
reproductive age. The needs of the growing fetus during pregnancy can contribute to these 
deficits (5). Low birth weight, premature birth, exposure to lead, exclusive breastfeeding 
past 4 months of age without iron supplementation, and inadequate amounts of iron-
fortified foods after weaning, particularly to whole cows’ milk increase the risk of iron 
deficiency anemia in children (22). Iron deficiency anemia is a risk factor for poor cognitive 
and psychomotor development (23-25).  
Iron as a Predictor of Illness 
Iron deficiency anemia has been associated with impaired immunity and increased 
susceptibility to infections (2, 3). In a study by Damodaran et al. (14), 383 preschool 
children in two Indian villages, Anajpur and Masjidpur, were given either a placebo or a 
supplement of 20 mg elemental iron and 100 ug folate per day during the first year of life. 
Anemia was diagnosed in 11% of the treatment group compared to 26% of the control 
group after 12 months of treatment.  The difference in anemia between the control and 
treatment groups was significant (p<0.02). The mean hemoglobin was higher in the 
treatment group than in the control group in the village of Anajpur at both 6 months of age 
(12.1 versus 11.6; p<0.05) and 12 months of age (12.4 versus 11.9; p<0.05). The Masjidpur 
village also showed a significant difference in the mean hemoglobin of treatment and 
control groups at 6 (11.3 versus 10.5; p<0.05) and 12 (12.5 versus 11.4; p<0.05) months of 
age; however, the study found no difference in the frequency or duration of respiratory or 
enteric infections between infants who were supplemented and infants who were not.  
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Cantwell (13) studied 238 Maori infants treated with injections totaling 250 mg iron 
dextran or not in the infants first week of life. According to the World Health Organization’s 
definition of anemia, 75-80% of Maori infants are anemic between 6-11 months of age. Per 
100 cases in the control group 42.4 were hospitalized for infections within the first two 
years of life compared to 31.9 hospitalizations in the treatment group. The number of 
hospitalizations for infections was 34% higher in the control group. The difference in 
hospitalizations between the control and treatment groups was statistically significant. In 
further analysis, the author eliminated wheezy bronchitis from the list of infections due to 
allergic origin and relationship to family history. He stated there was a difference in the 
number of hospitalizations; however, he did not provide a p-value for the difference in 
control and treatment groups. Maori infants were rarely fed iron supplemented formulas 
during the clinical trial. These two studies [Damodaran et al. (14) and Cantwell (13)] 
provide different evidence for the effects of post-natal supplementation of iron on infant 
and child illness, however, they differed in the way supplementation was given and were 
two different populations.  
Iron Supplementation during Pregnancy 
Eighty percent of the fetus’ iron accumulation occurs during the third trimester 
(22). Birth hemoglobin serves as an iron source for the first 4-6 months of life in breastfed 
infants (26).  Term infants are typically born with a high hemoglobin concentration.  
The National Health and Nutrition Examination Survey (NHANES) in 1988-94 (27) 
found that 72% of pregnant women used iron supplements and that the mean consumption 
of these supplements exceeded the tolerable upper limit of 45mg/d by 13mg/d. Fewer than 
15% of women of reproductive age taking iron supplements were being treated for anemia. 
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The use of iron supplements without diagnosis of iron deficiency anemia is controversial 
and may increase the risk of adverse pregnancy outcomes (28).  Iron supplementation in 
pregnancy can elevate hemoglobin, hematocrit, and serum ferritin (29). During the third 
trimester, serum ferritin levels >41ng/mL were associated with increased risk of a preterm 
and very preterm delivery (8). Hemoglobin >130g/L in the first trimester poses risk of 
preterm delivery and low infant birth weight (9). On the other hand, Scalon et al. (10) did 
not find that high hemoglobin during the 1st or 2nd trimester was associated with increased 
risk of preterm delivery. Allen (30) attributes iron deficiency anemia to hypoxia, oxidative 
stress, and infection after preterm delivery. 
Methods to Evaluate Iron Status  
Iron deficiency cannot be established by a single laboratory measurement. (22). 
Hemoglobin lacks sensitivity and can be affected by chronic infections and genetic 
disorders (31). Thus, serum transferrin receptor, reticulocyte hemoglobin, or serum 
ferritin in combination with hemoglobin are used to establish iron deficiency (22). Serum 
ferritin lab values can be altered by inflammation, but C-reactive protein values can 
confirm or exclude the possibility of inflammation. Serum transferrin receptor and 
reticulocyte hemoglobin are not affected by inflammation, however, serum transferrin 
receptor values have not been standardized in infants and children (32).  
Cook, Flowers, and Skikne (32) proposed another measure of iron status, body iron. 
Body iron is the ratio of serum transferrin receptor (TfR) to serum ferritin (F). The total 
body iron equation is: body iron (mg/kg) = -[log(TfR/F ratio) – 2.8229]/0.1207. A positive 
body iron concentration signifies iron storage while a negative value characterizes a 
depletion of iron stores. The body iron calculation may be applied to all blood samples 
 8 
analyzed for TfR and F, however, studies in infants have not validated the method. In young 
children and pregnant women repeated laboratory tests indicate the validity of the body 
iron value. The total body iron equation does have limitations. Serum ferritin lab values can 
be altered based on inflammation or liver disease and serum transferrin receptor values 
are not comparable for all commercial enzyme-linked immunosorbent assays.  
Relationship Between Maternal and Neonatal Iron Status  
 The relationship between maternal and neonatal iron status continues to be 
investigated and remains controversial. Two clinical trials evaluated the relationship 
between maternal and neonatal iron status after maternal iron supplementation during 
pregnancy. Zhou, Gibson, and Makrides (12) found no significant effect on hemoglobin or 
serum ferritin laboratory values in children born to women who took an iron supplement 
of 20 mg/day during pregnancy. A total of 430 non-anemic pregnant women were 
randomized to receive the supplement or a placebo from 20 weeks gestation until birth. 
Hemoglobin values at 6 months and 4 years of age were positively correlated and 
statistically significant for the children at (p<0.01). Maternal hemoglobin at delivery was 
positively related to child hemoglobin at 4 years of age (p=0.03). There were no other 
statistically significant relationships in the trial. Preziosi et al. (33) did find higher serum 
ferritin in infants born to iron-supplemented mothers. They randomized 197 pregnant 
women in Niger, in Western Africa, to receive 100 mg per day of elemental iron or a 
placebo from enrollment to birth. Maternal blood samples were collected at 6 months 
gestation, 28 weeks ± 21 days gestation, at labor, and again at 3 and 6 months postpartum. 
Neonatal cord blood and infant blood at 3 and 6 months of age were obtained. Iron status 
was evaluated based on hemoglobin, mean corpuscular volume, serum iron, transferrin 
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saturation, erythrocyte protoporphyrin, and serum ferritin laboratory values. Differences 
between cord blood values in the placebo and treatment groups were not statistically 
significant. Serum ferritin was significantly higher in infants born to iron-supplemented 
mothers. At 3 months (80±53 versus 99±63; p<0.05) and 6 months of age (15±20 versus 
26±27; p<0.05). The results of Preziosi et al. (33) suggest that infants born to iron 
supplemented mothers have better iron stores even though this is not apparent in iron 
measures taken at birth. 
The sole source of neonatal iron during pregnancy is maternal iron (6). Several 
studies have investigated the relationship between maternal and neonatal iron status. 
Hokama et al. (6) divided a small group of women (n=53) into three groups after delivery: 
a) those with iron deficiency anemia defined as hemoglobin ≤11.0g/dl and serum ferritin 
≤7.1ng/ml, b) those without iron deficiency but with low iron stores defined as hemoglobin 
>11.0g/dl and serum ferritin ≤7.1ng/dl, and c) those who were not anemic with good iron 
stores defined as hemoglobin >11.0g/dl and serum ferritin >7.1ng/dl. The researchers did 
not find significant differences in the mean values of infant‘s cord blood hemoglobin, serum 
iron, or total iron binding capacity between groups, however, the mean values of serum 
ferritin differed among the three groups (p<0.10). The lowest mean serum ferritin values 
were observed in infants born to iron deficient mothers.  
Savoie and Rioux (11) studied medical records of 75 mothers and their neonates. 
The mothers were divided into two groups (anemic and non-anemic) based on iron status 
in the 3rd trimester. Maternal anemia was defined as hemoglobin <110g/L and hematocrit 
<33%. Infant anemia was defined as hemoglobin <110g/L and infant iron-deficiency 
anemia was defined as hemoglobin <110g/L and serum ferritin <10ug/L. The researchers 
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found a positive correlation between the mother’s hemoglobin and hematocrit during the 
3rd trimester and measures in the infants hemoglobin (p=0.02, r2=0.10) and hematocrit 
(p=0.04, r2=0.08). at 9 months of age. They also found that infants born to anemic mothers 
were more likely to be diagnosed with iron-deficiency anemia (p=0.055). At 9 months of 
age, there was no difference in the mean values of hemoglobin, hematocrit, serum ferritin, 
or mean corpuscular volume between infants born to non-anemic or anemic mothers at 9 
months of age.  
The placenta acts as the nutrient transporter between the mother and fetus (7). The 
placenta transfers iron to the fetus across the syncytiotrophoblast against a concentration 
gradient. Young et al. (7) investigated the possibility of this mechanism’s ability to respond 
to iron deficiency in the fetus. The researchers compared placental TfR production in 
ninety-two healthy pregnant adolescents and their neonates. Placental transferrin receptor 
increases in iron deficiency, and is associated with iron demands (7). Subjects were 
supplemented with 27 mg of iron for an undisclosed period of time. Placental tissue was 
analyzed for TfR concentration as were cord blood and maternal blood draw at 21-25 
weeks gestation and delivery. Infants with serum ferritin concentration ≤34ug/L had 
elevated placental TfR compared to infants with serum ferritin concentrations >34ug/L 
(p<0.01).  Placental TfR concentration was inversely associated with total body iron at 
delivery (p<0.02). 
Predictors of Iron Status  
Hay et al. (34) studied 364 mothers and their infants to determine predictors of 
serum ferritin and serum TfR, a representative of iron storage and needs. Maternal body 
mass index (BMI) measured in the first-trimester was not correlated with maternal serum 
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ferritin, however, cord blood serum TfR was positively related to BMI (p=0.20, P=0.001). 
Gestational age was positively correlated with both cord blood serum ferritin (p=0.13, 
P=0.016) and cord blood serum TfR (p=0.24,P<0.001).  
 Pregnant women were categorized as smokers or nonsmokers (34). Occasional 
smokers were included with nonsmokers for statistical analysis. There was not a significant 
difference in cord serum TfR based on smoking status, but cord serum ferritin values were 
lower in infants born to smoking mothers (p=0.025), evidence of lower iron status.  
 Adebisi and Strayhorn (35) used data from the US 1995-2000 natality files to 
determine if maternal ethnicity and the occurrence of anemia during pregnancy were 
related. The natality data was collected by the National Center for Health Statistics under 
the direction of the Centers for Disease Control and Prevention. The study found that non-
Hispanic black mothers were twice as likely (35/1000) as non-Hispanic white mothers 
(18/1000) to be anemic during pregnancy. Adebisi and Strayhorn did not specify anemia as 
iron deficiency anemia in their study.  
Summary 
 
Iron deficiency is the most prevalent nutritional deficiency in the world. It can 
hinder productivity, cognitive and psychomotor development and iron deficiency imposes 
health consequences that are particularly devastating in the developing world where 
deficiency tends to be very severe (4).  
In two clinical trials, neonatal serum ferritin values were influenced by whether the 
neonate was born to an iron deficient mother or a mother with normal iron stores (6, 33). 
In each of these studies, mean values of serum ferritin differed significantly among infants 
born to iron deficient mothers, mothers with low iron stores, and mothers with adequate 
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iron stores. Serum ferritin values were also found to be significantly higher in infants born 
to iron-supplemented mothers.  
Infants born to anemic mothers appear to have lower iron status and may be more 
likely to have a diagnosis of iron-deficiency anemia based on a positive correlation between 
the mother’s hemoglobin and hematocrit during the 3rd trimester and the infants at 9 
months of age (11).  
One study showed post-natal iron supplementation in infants decreased the number 
of hospitalizations in the first two years of life (13). Another study investigating the effects 
of post-natal iron supplementation showed there was no difference in the incidence of 
enteric or respiratory infections in the first year of life (14). The two study populations and 
the way the supplement was given differed.  
No published reports of body iron to assess iron status in neonates exist to my 
knowledge. As with other age groups, body iron may be a more informative measurement 























Subjects were a convenience sample from a phase III randomized control trial of 
docosahexaenoic acid (DHA) supplementation during pregnancy titled “The Effect of DHA 
on Pregnancy Outcome”. The present proposal was to investigate the relationship between 
maternal and infant body iron and infant illness.   
The primary investigation recruited 350 pregnant women between 8 and 20 weeks 
gestation. The subjects were recruited from local Kansas City hospitals including Kansas 
University Medical Center, St. Luke’s Hospital, and Truman Medical Center; and by word of 
mouth, and website advertising (broadcasts to KUMC faculty and staff). The inclusion 
criteria were: ages 16-35.99 years of age, willing to consume three capsules daily, BMI <40, 
planned to deliver the infant at the study center hospital, availability by telephone, and 
absence of illnesses that could adversely influence infant growth and development. For 
example, women were excluded with some chronic illnesses such as high blood pressure 
(systolic ≥140mm Hg), diabetes, or morbid obesity. Women were also excluded if they 
were unable to provide consent in English or had a multiple birth pregnancy. 
Infants of all study subjects who had reached one year of age before December 2010 
were included in the present analysis if they also had medical records and blood samples. 
One eligible subject was excluded due to sudden infant death syndrome and another was 
excluded due to diagnosis of cystic fibrosis. There were 199 mother-baby pairs available 
for analysis.  
The primary study design was a randomized, placebo-controlled phase III clinical 
trial (36). The intervention was consumption of three capsules of either a corn/soy oil 
based placebo or an algal oil to provide 600mg/day of docosahexaenoic acid.  The study 
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primary outcomes were gestation duration, visual and cognitive development, and 
maternal red blood cell fatty acids. This clinical trial is registered at clinicaltrials.gov as 
NCT00266825.  
The study setting was the University of Kansas Maternal and Child Nutrition 
Development Laboratory in Kansas City, Kansas (36).  
The Human Subject Committee, Institutional Review Board, at the University of 
Kansas Medical Center, St. Luke’s Hospital of Kansas City, Missouri, and the University of 
Missouri, Kansas City approved the primary study (36).  The Kansas University Medical 
Center Human Subjects Committee (HSC) approval number is 10186. The privacy board at 
Truman Medical Center and St. Luke’s hospital approved the primary study. The secondary 
analysis for the present proposal utilized data collected under an approved amendment by 
the KUMC HSC and served as the informed consent (see Appendix A). 
Adverse Events  
The incidence of illness was recorded based on medical records and parent report of 
events at routine (6 weeks, 4, 6, 9, 10, and 12 months) infant clinic visits. Adverse events 
were recorded and coded into a Microsoft Access database (Microsoft Windows 2007, 
Seattle, Washington, USA) modified from one used in a previous study (36) (also see 
Appendix B, C). Medical records were requested immediately after each child’s first 
birthday (see Appendix D). All accounts of infant illness were retrieved from the database 
for subjects until one year of age. Only subjects who reached one year of age by December 
2010, were included to allow time to receive and code the medical records prior to data 
analysis (see Appendix E).  
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Body Iron Assessment  
Hematologic values were obtained from medical records to be used in data analysis 
and calculations of iron status, as described below.  
The calculation of body iron in maternal and neonatal blood was used to assess the 
relationship between the two at delivery. The total body iron equation is: body iron 
(mg/kg) = -[log(TfR/F ratio) – 2.8229]/0.1207. The TfR/F ratio is the ratio of serum 
transferrin receptor to serum ferritin (32). Body iron was determined on maternal 
postpartum blood and neonatal cord blood. Analyses for serum ferritin and serum TfR 
values were completed by Elizabeth Kerling, MS, RD. Body iron (mg/kg) has the advantage 
that only two specific measures of iron status are needed to determine iron status, 
however, as noted earlier, body iron has not been validated for use with infants. The 
present study will make such an evaluation. 
Statistical Analysis  
Maternal body iron and infant body iron were compared by Pearson’s correlation 
coefficient. Correlations between maternal plasma ferritin, 28-week hemoglobin, maternal 
plasma TfR, cord blood and 4 month plasma ferritin and plasma TfR, gestational days 
smoked, ethnicity, iron supplement use during pregnancy, infant feeding (human milk vs. 
formula), and maternal body mass index were analyzed to determine other possible 
relationships.  
Linear regressions between the dependent variable, maternal postpartum body 
iron, and predictor variables, neonatal body iron from cord blood and 4-month neonatal 
body iron were completed.   
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Odds-ratios were used to determine the relative difference in incidence of infant 
illness among mothers and infants divided into four quartiles based on their iron values.  
Maternal body iron values for the four quartiles were: Quartile 1 (-6.8-2.3 mg/kg), Quartile 
2 (2.4-5.0 mg/kg), Quartile 3 (5.1-7.44 mg/kg), Quartile 4 (7.442-14.9 mg/kg). Maternal 
hemoglobin from 28-week gestation values were: Quartile 1 (8.4-11g/L), Quartile 2 (11-
11.5g/L), Quartile 3 (11.6-12.1-g/L), Quartile 4 (12.1-14g/L). 
Statistical analysis was performed using Predictive Analysis Software 18.0 (SPSS 




































My analysis included 199 pregnant women and their infants. The study population 
was 63.3% Caucasian, 30.2% African American, 5% Hispanic and 1.5% other. Twenty-one 
percent of the samples’ mothers took iron supplements, in addition to their prenatal 
vitamins, which contained a lower concentration of iron during pregnancy and 78.5% did 
not. The mean gestational age at delivery was 39.41 ± 1.46 weeks. The mean measured 
body mass index was 27.13 ± 5.24 kg/m2. Twenty percent of the sample breastfed for less 
than 6 days, 14.5% breastfed for 7-42 days, 10% breastfed for 43-120 days, and 37% 


















African American: 30.2% 
Hispanic: 5% 
Other: 1.5% 






Mean ± SD:  
39.41 ± 1.46 weeks 
Body Mass Index 
n=165 
Mean ± SD:  




0-6 days BF: 20% 
7-42 days BF: 14.5% 
43-120 days BF: 10% 










Iron status indicators are shown in Table 2. 
Table 2. Iron Status Indicators 














8.41 ± 2.74  
(0-15) 
n=130 
8.852 ± 2.93 
(.85-19.73) 
n=132 




Infant Blood at  
4-months of age 
 
6.30 ± 2.72  
(-4-12) 
n=96 








Mother at Delivery 
 
4.55 ± 3.95 
(-7-15) 
n=194 
5.11 ± 2.7 
(1.22-19.52) 
n=194 
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Relationship between Maternal and Infant Body Iron  
 
The relationship between maternal postpartum body iron and birth and 4-month 
infant body iron is shown in Table 3. Maternal postpartum plasma ferritin was negatively 
correlated with 4-month neonatal body iron (r=-.229, p=.029). The correlation suggests 
birth iron may not be the best indicator of iron status, and suggests the fetus’ iron may get 



















Table 3. Correlation between Maternal Postpartum Body Iron and Infant Body Iron  
 Maternal  
Body Iron  
Maternal  
Transferrin Receptor  
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Plasma Ferritin  
 

















































Plasma Ferritin  

























Linear regression did not show a significant association between maternal 
postpartum body iron and birth and 4-month infant body iron.  Maternal postpartum body 
iron accounted for only 0.3% of the variance in neonatal body iron from cord blood 
(R2=.003). Maternal postpartum body iron accounted for only 2% of the variance in 4-
month infant body iron, was (R2=.019).  Neither suggests any relationship. However, 
maternal ferritin was related to 4-month infant body iron.  
Iron and Incidence of Infant Illness 
The relationship between iron status of the mother and infant illness in the first 












Table 4. Correlation between Maternal Iron Status and Incidence of Infant Illness 


































































Maternal transferrin receptor and occurrence of eyes, ears, nose, and throat 
illnesses were inversely correlated at (r=-.138, p=.054) (see Table 4).  
The relationship between iron status of the infant and infant illness in the first year 
of life is shown in Table 5. No significant correlation was found between infant illness in 
the first year of life and infant iron status. Non significant trends between neonatal plasma 
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ferritin (r=-.144, p=.099), neonatal plasma transferrin receptor (r=-.158, p=.070) and 
occurrence of eyes, ears, nose, and throat illness were inversely correlated. The non 






















Table 5. Correlation between Neonatal Iron Status and Incidence of Infant Illness  
 EENT RESP GI TOTAL OM URI 
Neonatal  
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 Potential iron effectors including: formula feeding, maternal ethnicity, gestational 
days smoked, and iron supplementation during pregnancy were correlated with iron 
laboratory values. Days formula fed was significantly correlated with 4-month body iron 
(r=.313, p=.008). Maternal ethnicity (r=.229, p=.002) was correlated with hemoglobin at 28 
weeks gestation and iron supplementation during pregnancy (r=-.322, p=.000) was 
inversely correlated with hemoglobin at 28 weeks gestation. Gestational days smoked 
correlated inversely with plasma ferritin from cord blood (r=-.203, p=.019). 
The quartiles maternal body iron, and maternal 28-week hemoglobin, was unrelated 
to the incidence of EENT, RESP, or GI infant illness (see Table 6, 7, 8). The percentage of 
infants diagnosed with an EENT, RESP, or GI illness did not trend up across quartiles with 
poorer iron status. Quartile 1 contains infant illness data for infants whose mothers had a 
maternal body iron value between (-6.8-2.3 mg/kg) and 28-week hemoglobin between 
(8.4-11g/L). Quartile 2 maternal body iron values were between (2.4-5.0 mg/kg) and 28-
week hemoglobin (11-11.5g/L). Quartile 3 maternal body iron values were between (5.1-
7.44 mg/kg) and 28-week hemoglobin (11.6-12.1-g/L). Quartile 4 maternal body iron 







Table 6. Maternal Iron Status related to Incidence of EENT Infant Illness 




















Maternal Hgb  















*Numerator is the number of study subjects infants diagnosed with an EENT illness. 
Denominator is the number of study subjects infants in each quartile (n).  
**Percentage of infants with an EENT illness from that quartile.  
 
Table 7. Maternal Iron Status related to Incidence of RESP Infant Illness  























Maternal Hgb   















*Numerator is the number of study subjects infants diagnosed with a RESP illness. 
Denominator is the number of study subjects infants in each quartile (n). 





Table 8. Maternal Iron Status related to Incidence of GI Infant Illness 























Maternal Hgb  















*Numerator is the number of study subjects infants diagnosed with a GI illness. 
Denominator is the number of study subjects infants in each quartile (n). 






























My analysis did not find a significant relationship between maternal and neonatal 
iron status determined by the body iron equation on the incidence of first year illness. The 
study further showed no significant association between maternal postpartum body iron 
and birth and 4-month infant body iron. Damodaran et al. (14) found no difference in the 
frequency or duration of respiratory or enteric infections in two Indian villages of iron 
supplemented preschool children (n=383). These study results are similar with my 
analysis, however, it is important to note the study population in Damodaran et al. had a 
much higher risk of infection and most likely malnutrition. Although, non significant trends 
between neonatal serum ferritin (r=-.144, p=.099), neonatal serum transferrin receptor 
(r=-.158, p=.070) and occurrence of eyes, ears, nose, and throat illness were found and 
inversely correlated. The non significant trends suggest an inverse relationship between 
EENT illness and poorer iron status. Although, there was no significant association between 
maternal and infant body iron at birth it is important to note maternal postpartum serum 
ferritin was negatively correlated with 4-month neonatal body iron (r=-.229, p=.029) 
suggesting a possible redirection in iron transfer to the fetus which could occur under 
some circumstances (5). Neonatal body iron from cord blood and 4-month neonatal body 
iron were positively correlated and statistically significant (r=.240, p=.047). The finding is 
small, but a significant relationship between maternal iron status at delivery and infant 
iron status at 4-months of age. Additionally, the finding is similar to results of Zhou, Gibson, 
and Makrides (12) regarding hemoglobin. Neonatal serum ferritin from cord blood and 4-
month serum ferritin were correlated (r=.390, p=.001). These correlations demonstrate 
that iron status of infants at birth predicts iron status in early infancy. The correlations 
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suggest maternal body iron at birth and infant cord blood is not a good indicator of 
maternal or infant iron status but that body iron may be a good indicator.  
Limitations  
The total body iron equation does have limitations. Serum ferritin lab values can be 
altered based on inflammation or liver disease. Serum TfR values may not be comparable 
between or among studies because there are a variety of enzyme-linked immunosorbent 
assays. A limitation is the absence of C-reactive protein values, an indicator of inflammation 
(16). Individuals diagnosed with liver disease did not meet inclusion criteria. In young 
children and pregnant women repeated laboratory tests indicate the authenticity of the 
body iron value (16). 
There was potential for human error in recording and coding medical records. One 
individual recorded and coded medical records and then a study coordinator checked 
recording and coding to reduce potential error.  Medical records confirmed report of 
adverse events. In the event the subject was not seen at a hospital or clinic, parent report 
was the only source of adverse events.  
The subject’s parent or guardian reported clinics and hospitals visited for adverse 
events. If a parent or guardian does not provide a location the subject previously visited to 
the study team, medical records are not received from this institution. This limitation can 
cause misrepresentation of incidence of illness.  
Subjects used for my analysis were a convenience sample from a phase III 
randomized control trial of docosahexaenoic acid (DHA) supplementation during 
pregnancy. Half of the pregnant mothers were supplemented with 600mg/d of 
docosahexaenoic acid or a corn/soy oil placebo. Researchers (37) have found infants 
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supplemented with DHA have a reduced incidence of upper respiratory infections, 
wheezing, asthma, and allergic diseases. The reduced number of illnesses has been shown 
in children up to three years of age (37). DHA in supplemented mothers may have affected 
the incidence of illness in their infant’s first year of life.  
Neonatal hemoglobin values were unavailable for study infants. Hemoglobin 
provides adequate iron for the first 4-6 months of life in breastfed infants (26) and could 
have provided an additional iron status measure. Hemoglobin could potentially better 
predict illness rates in the first year of life.   
Subjects were not divided into groups based on ethnicity for the purpose of 
statistical analysis.  
Future Studies  
Future studies should be conducted to further examine birth iron status as a 
predictor of infant iron status. Future studies should focus on the potential influence of 
maternal serum ferritin on neonatal iron status. As previously stated, a single 
measurement cannot characterize iron status. Researchers may consider expanding the 
number of iron markers to include mean corpuscular volume, serum ferritin, serum 
transferrin receptor, transferrin saturation, and reticulocyte hemoglobin.  
Conclusion  
Although not a primary research question outcome, this secondary analysis 
provides evidence that iron status at birth continues to influence iron status at 4-months of 
age as evidenced by serum ferritin and body iron concentrations. The evidence that body 
iron declines through a period of infancy has been discovered in past research regarding 
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hemoglobin (22). Future studies expanding the length of study and the number of iron 















































The purpose of this secondary analysis was to compare maternal postpartum iron 
stores, serum transferrin receptor and serum ferritin, to birth and 4 month infant iron 
status and to compare maternal and newborn iron status at birth to the incidence of infant 
illness in the first year of life. Maternal postpartum serum ferritin, postpartum serum 
transferrin receptor, 28-week hemoglobin, and neonatal serum transferrin receptor, and 
serum ferritin at birth and 4-months were collected in the primary study and used to 
establish iron status in the secondary analysis. Subjects were a convenience sample from a 
phase III randomized controlled trial studying docosahexanoic acid in pregnancy. Medical 
records and parent reported adverse events at routine clinic visits determined incidence of 
infant illness in the first year of life. The secondary analysis results showed no statistical 
significance between maternal and neonatal body iron and no significance between 
maternal or neonatal body iron and first year illness. However, maternal postpartum 
serum ferritin was significantly correlated with 4-month neonatal body iron. Neonatal 
body iron from cord blood and 4-month infant body iron were also positively correlated at 
statistical significance.  
Prior research by Damodaran (14) supports the secondary analysis results stating 
there is no relationship between newborn or maternal iron status and the incidence of first 
year illness.  
These results suggest iron status at birth may predict iron status in 4-month infants 
and maternal postpartum serum ferritin could predict iron status at 4-months of age. To 
conclude iron status at birth may predict long-term iron status in pediatric populations will 
need future research. 
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Eyes, Ears, Nose, Throat 
(EENT) Diagnosis 
Adverse Events Included 
 
• Abnormal Refraction 
• Allergic Conjunctivitis  
• Allergic Rhinitis 
• Allergic Rhino-conjunctivitis 
• Allergic Sinusitis 
• Bacterial eye infection 
• Blind 
• Cataracts 
• Choanal Stenosis  
• Conjunctivitis 
• Corneal Abrasion 
• Ear Drainage 
• Ear Wax Excessive 
• Eye Movement Disorder 
• Eyelid Infection 
• Hearing Deficit 
• Hemangioma 
• Infectious Conjunctivitis 
• Infectious Rhinitis 
• Infectious Sinusitis 
• Laryngeal edema 
• Laryngomalacia 
• Laser Surgery/Cryotherapy 
• Myringotomy/TM Tubes 
• Nasal Congestion 
• Nasal/Tear Duct Obstruction 
• Otitis Externa 
• Otitis Media 
• Purulent Rhinitis 
• Retinal Detachment/Hemorrhage 
• Retinopathy of prematurity 
• Rhinorrhea 
• Septal Deviation 
• Sneezing/itching 
• Staph infection in the eye 




• Tugging at Ear 
• Varix 
• Watery Eye 
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Gastrointestinal (GI) Diagnosis • Abdominal Cramping 
• Abdominal Distention 
• Acute Gastroenteritis 
• Allergic Colitis 
• Allergic Enterocolitis 
• Allergic Esophagitis 
• Allergic Gastroenteritis 
• Anal Fissure 
• Anal Irritation 
• Anal Swelling 
• Bloating 





• Cow’s Milk Intolerance 




• Excessive Spitting 
• Feeding Problems 
• Feedings withheld due to Intolerance 
• Flatulence 
• Frequent Stools 
• G.E. Reflux 
• Gas 
• Gastric Residuals 
• Gastric Tube Placement 
• GI Infection 
• Hard Stools 
• Hemorrhoid 
• Hepatic Calcification 
• Hunger 
• Necrotizing Enterocolitis 
• Perianal Fistula 
• Perirectal abscess 
• Persistence of Umbilical Cord 
• Pyloric Stenosis 















Respiratory (RESP) Diagnosis 
• Salmonella in Stool 
• Spitting Up 
• Stomatitis 
• Straining 
• Umbilical Hernia 
• Rotavirus 
• Stomatitis 
















• Positive Pressure Ventilation 
• Pulmonary Edema 
• Pulmonary Hypertension 
• Pulmonary Insufficiency 
• Reactive Airway Disease 
• Reintubation 
• Respiratory Distress Syndrome 
• Respiratory Syncytial Virus 




• Wheezing  
Upper Respiratory Infections 
(URI) 
• URI alone 




























































Adverse Event Log Sheet 
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